Oncolix, Inc. Forms Scientific and Clinical Advisory Board and Appoints First Member

July 17, 2018 7:20 AM

HOUSTON, TX / ACCESSWIRE / July 17, 2018 / Oncolix, Inc. (OTCQB: ONCX) (the "Company"), a biotechnology company focused on gynecological cancers, announced that the Company has appointed Robert Niecestro, PhD as its first member of its Regulatory Strategy, Scientific and Clinical Advisory Board. "Dr. Niecestro is a valuable resource to Oncolix because we want to properly navigate Prolanta and new acquisitions through the worldwide regulatory...

Read more

AcuityBio Corporation to Present at the 144th NIBA Investment Conference

July 16, 2018 8:00 AM

NEW YORK CITY, NY / ACCESSWIRE / July 16, 2018 / AcuityBio Corporation (www.acuitybio.com) is a private company, focused on preventing post-surgical lung cancer recurrence via targeted drug-delivery. AcuityBio's first product candidate is "ABC103," their innovative drug-device combination product, which has been granted FDA Orphan Drug designation. AcuityBio announced today that its CEO, Dr. John 'Jay' Schwartz will be describing their ABC103...

Read more

American CryoStem Announces Launch of ATGRAFT(TM) in China

July 12, 2018 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / July 12, 2018 / American CryoStem Corporation (OTC PINK: CRYO), a leading strategic application developer, marketer, and global licensor of patented adipose tissue-based cellular technologies, for the Regenerative and Personalized Medicine industries, today announced the national launch of CRYO's ATGRAFTTM tissue collection, processing and storage technology by Baoxin Asia Pacific Biotechnology (Shenzhen) Co. Ltd....

Read more

MorphoSys Announces its Licensee Janssen has Initiated a Phase 2/3 Program (GALAXI) to Evaluate Tremfya(R) (Guselkumab) in Crohn's Disease

July 10, 2018 4:25 PM

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 10, 2018 / MorphoSys AG (NASDAQ: MOR), (FSE: MOR), (XETRA: MOR) announced today that its licensee Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), has initiated a pivotal phase 2/3 clinical program to evaluate the efficacy and safety of Tremfya(R) (guselkumab) in the treatment of patients with moderately to severely active...

Read more

Oncolix, Inc. Expands Management Team with New Vice President of Corporate Development

July 5, 2018 7:20 AM

HOUSTON, TX / ACCESSWIRE / July 5, 2018 / Oncolix, Inc. (OTCQB: ONCX) (the "Company"), a biotechnology company focused on gynecological cancers, announced that Andrew Scott has joined the Company as its Vice President of Corporate Development. "Andrew is a seasoned veteran that understands the important roles of Investor Relations, banking relationships and raising capital," said Michael T. Redman, president and chief executive officer of...

Read more

Calmare Therapeutics Incorporated Reports Final Tally of Consents by Shareholders of Record

July 2, 2018 5:35 PM

FAIRFIELD, CT / ACCESSWIRE / July 2, 2018 / Calmare Therapeutics Incorporated, (OTC PINK: CTTC) ("CTI"), the pain mitigation company ("Calmare"), today reported the final tabulation of consents by shareholders of record as tallied and prepared by IVS Associates Inc., a professional services organization specializing in independent tabulation and certification of voting results. As per the final tally, none of the proposals carried. Out of...

Read more

Vitro Bio-Pharma 2nd Quarter Ended April 30th 2018 Financial Results of Operations

June 26, 2018 11:00 AM

GOLDEN, CO / ACCESSWIRE / June 26, 2018 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro BioPharma, announced its 2nd quarter ended April 30th 2018 financial results of operations. Vitro Diagnostics Inc. (''Vitro'') is pleased to announce a record 2nd quarter in Stem Cell Revenues. Vitro recorded 2nd quarter revenues of $125,886 vs $56,633 an increase of 222% over the same comparative quarter last year. In addition, Stem Cell therapies...

Read more

Oncolix, Inc. Appoints Wall Street Veteran, Sherry Grisewood, to Its Board of Directors

June 26, 2018 7:05 AM

HOUSTON, TX / ACCESSWIRE / June 26, 2018 / Oncolix, Inc. (OTCQB: ONCX) (the "Company"), a biotechnology company focused on gynecological cancers, announced that the board of directors elected veteran Wall Street healthcare professional Sherry Grisewood to the Company's Board of Directors as an independent board member. She will be the fifth member on the Board of Directors and the third independent board member. "Sherry is an accomplished Wall...

Read more

Food & Beverage/Consumer Packaged Goods Industry Veteran Joins ZIVO Bioscience, Inc. as VP - Global Operations

June 21, 2018 8:00 AM

KEEGO HARBOR, MI / ACCESSWIRE / June 21, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from its proprietary algal strains, announces today that Ronald C. Costephens has joined the Company as Vice-President- Global Operations. Mr. Costephens is charged with building out a global supply chain and an organization to help transition ZIVO from...

Read more

Molecular Partners Appoints Pamela A. Trail as Chief Scientific Officer; Michael T. Stumpp Assumes Role of Chief Operating Officer of the Company

June 21, 2018 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 21, 2018 / Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, announced today the appointment of Pamela A. Trail, Ph.D., as Chief Scientific Officer. Pamela Trail served most recently as Vice President of Oncology Strategy and Program Direction at Regeneron Pharmaceuticals. With her addition, the company...

Read more

American CryoStem to Develop Standardized Tissue Scoring System

June 19, 2018 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / June 19, 2018 / American CryoStem Corporation (OTC PINK: CRYO), a leading strategic application developer, marketer, global licensor of patented adipose tissue-based cellular technologies, for the Regenerative and Personalized Medicine industries, today announced a new scientific project to create a Histological Scoring System for Collected Lipoaspirate. This project is based upon the Company's extensive experience...

Read more

MorphoSys Presents Clinical Data with Blood Cancer Candidate MOR208 in Chronic Lymphocytic Leukemia at EHA 2018 Conference

June 15, 2018 2:59 AM

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 15, 2018 / MorphoSys AG (NASDAQ: MOR), (FSE: MOR), (XETRA: MOR) today announced the presentation of clinical data from the exploratory phase 2 COSMOS trial. The trial evaluates MorphoSys's proprietary hemato-oncological drug candidate MOR208 in combination with the cancer drug idelalisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL),...

Read more

MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at EHA 2018

June 15, 2018 2:44 AM

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 15, 2018 / MorphoSys AG (NASDAQ: MOR), (FSE: MOR), (XETRA: MOR) today presented updated data from the ongoing phase 1/2a study of the anti-CD38 antibody MOR202 in relapsed/refractory multiple myeloma at the European Hematology Association (EHA) Annual Meeting 2018 in Stockholm. The dose escalation trial comprises three arms: MOR202, MOR202 in combination with the immunomodulatory drug (IMiD)...

Read more

Molecular Partners Presents Updated Results From its Ongoing Phase 2 Combination Study of its Lead Oncology Drug MP0250 at EHA in Stockholm

June 15, 2018 1:00 AM

MP0250 is evaluated in combination with Velcade/Dexamethasone (VelDex) in relapsed/refractory multiple myeloma (MM) patients Five of eight patients (62.5%) with relapsed/refractory multiple myeloma showed an objective response to MP0250 plus VelDex Median duration on treatment for patients with response was 22.5 weeks Main adverse events were hypertension, thrombocytopenia and upper respiratory tract infection,...

Read more

Calmare Therapeutics Reports Preliminary Tally of Consents by Shareholders

June 14, 2018 6:25 PM

FAIRFIELD, CT / ACCESSWIRE / June 14, 2018 / Calmare Therapeutics Incorporated (OTC PINK: CTTC) ("CTI"), a pain mitigation company ("Calmare"), today reported the preliminary tally of consents by shareholders with respect to a recent consent solicitation neither supported by Calmare's officers nor by four of its five directors. This preliminary tally is based on information prepared by IVS Associates Inc., a professional services organization...

Read more

New Phase 3 Clinical Trials by MorphoSys's Partner with Gantenerumab in Early Alzheimer's Disease now Underway

June 12, 2018 4:22 PM

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 12, 2018 / MorphoSys AG (NASDAQ: MOR, OTC PINK: MPSYY, FSE: MOR, XETRA: MOR, Prime Standard Segment, TecDAX) announced today that the first patient has been enrolled in a new phase 3 trial of gantenerumab in patients with early Alzheimer's disease. Gantenerumab is a monoclonal antibody directed against amyloid-beta generated by MorphoSys using its proprietary HuCAL antibody technology. Roche is...

Read more

Pressure BioSciences Converts Additional $7.24M of Debt into Equity: Total Conversions Exceed $13.6M in Past 30 Days

June 12, 2018 9:00 AM

2015/2016 Debentures, Line-of-Credit, Promissory Note, & Misc. Short-Term Debt All Converted into Equity; Investors Signal Strong Support for Company's Planned 2018 Up-List SOUTH EASTON, MA / ACCESSWIRE / June 12, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform solutions to the worldwide life sciences...

Read more

Oncolix, Inc. Completes $1.2 Million Financing and Restructures Existing Debt

June 5, 2018 4:50 PM

HOUSTON, TX / ACCESSWIRE / June 5, 2018 / Oncolix, Inc., (OTCQB: ONCX) a clinical-stage biotechnology company ("Company") developing Prolanta™ for the treatment of ovarian cancer, today announced the restructuring of its existing debt issued in August 2017 and the issuance of new debt in the principal amount of approximately $1.2 million. "This financing was supported by the current noteholders and there was 100 percent participation,"...

Read more

MorphoSys to Present at Upcoming Investor Conferences

June 4, 2018 10:10 AM

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 4, 2018 / MorphoSys AG (NASDAQ: MOR, OTC PINK: MPSYY, FSE: MOR, XETRA, MOR, Prime Standard Segment, TecDAX) will present at the following conferences: dbAccess Berlin Date: June 6, 2018 Venue: Berlin, Germany Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG Dr. Verena Kupas, Manager Corporate Communications & IR JMP Securities Life Sciences Conference Date: June 20,...

Read more

AYOXXA launches LUNARIS(TM) Human & Mouse 6-Plex T Cell Characterization Kits to elucidate T cell differentiation

June 4, 2018 3:19 AM

LUNARISTM Human & Mouse 6-Plex T Cell Characterization Kits are validated for quantitative analysis of soluble effector molecules secreted by distinct T cell populations, including IFN-γ, IL-2, IL-4, IL-17A, TGF-β1, and Granzyme B The accurate and reproducible generation of biomarker profiles allows for the unraveling of an altered number or functions of differentiated T cell subsets and spots potential points on...

Read more